How Do We Measure What We Get When We `Buy' Research?

Editor's Note: Today's academic scientists are being asked more frequently than in the past to defend the value of their research. And the pursuit and acquisition of knowledge, once accepted at face value as positive objectives within a democratic society, are no longer good enough, by themselves, to justify scientific investigations. Politicians and the public now demand to know what they are getting for their money, and the most satisfying answers tend to be couched in terms of economic payo

Written byEdwin Mansfield
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

Editor's Note: Today's academic scientists are being asked more frequently than in the past to defend the value of their research. And the pursuit and acquisition of knowledge, once accepted at face value as positive objectives within a democratic society, are no longer good enough, by themselves, to justify scientific investigations. Politicians and the public now demand to know what they are getting for their money, and the most satisfying answers tend to be couched in terms of economic payoff to the citizenry as well as the creation of a more skilled labor force.

For a long time, nobody was able to quantify the impact that academic research was having on the industrial sector. Enter Edwin Mansfield, a professor of economics and director of the center for economics and technology at the University of Pennsylvania. In the mid-1980s, Mansfield decided to tackle the problem. Within a few years, he and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies